Atorvastatin lactone | CAS#125995-03-1 | atorvastatin prodrug

MedKoo Cat#: 530976 | Name: Atorvastatin lactone

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Atorvastatin lactone, also known as Atorvastatin Related Compound H, is a prodrug form of atorvastatin, an HMG-CoA reductase inhibitor used to lower blood cholesterol levels. It hydrolyzes rapidly to the acid form of atorvastatin in human serum.

Chemical Structure

Atorvastatin lactone

CAS#125995-03-1

Theoretical Analysis

MedKoo Cat#: 530976

Name: Atorvastatin lactone

CAS#: 125995-03-1

Chemical Formula: C33H33FN2O4

Exact Mass: 540.2424

Molecular Weight: 540.64

Elemental Analysis: C, 73.31; H, 6.15; F, 3.51; N, 5.18; O, 11.84

Price and Availability

Size	Price	Availability	Quantity
25mg	USD 350.00	2 weeks
100mg	USD 850.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

1044582 USP Atorvastatin Related Compound H,

IUPAC/Chemical Name

5-(4-Fluorophenyl)-1-{2-[(2R, 4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide

InChi Key

OUCSEDFVYPBLLF-KAYWLYCHSA-N

InChi Code

InChI=1S/C33H33FN2O4/c1-21(2)31-30(33(39)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-27-19-26(37)20-28(38)40-27/h3-16,21,26-27,37H,17-20H2,1-2H3,(H,35,39)/t26-,27-/m1/s1

SMILES Code

O=C(C1=C(C(C)C)N(CC[C@@H]2C[C@@H](O)CC(O2)=O)C(C3=CC=C(F)C=C3)=C1C4=CC=CC=C4)NC5=CC=CC=C5

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Atorvastatin is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.

In vitro activity:

The expression level of CD31, eNOS, podocalyxin, von Willibrand factor, and alpha-smooth muscle actin proteins was measured using the ELISA technique. Unlike ATO (Atovorstatin) 40 mg/kg, the results showed that ATO 2 mg/kg was significantly increased the levels of proteins mentioned above compared to the control group (P˂0.05) (Table 2). Reference: Eur J Pharmacol. 2021 Jul 1;907:174281. https://pubmed.ncbi.nlm.nih.gov/34217710/

In vivo activity:

To induce NASH, C57BL/6 male mice were fed an F diet over 24 weeks. In comparison with a chow diet, the F diet induced significant elevations in body weight; liver weight; liver to body weight ratio (%); serum alanine aminotransferase (ALT), an indicator of hepatocellular injury; alkaline phosphatase (ALP), a marker of cholestatic liver impairment; triglycerides (TG); and soluble endoglin (Figure 1)—a recently suggested marker of liver fibrosis in NASH . Atorvastatin effectively reduced plasma ALT and TG concentrations (Figure 1), indicating its positive effect on liver injury. Reference: Int J Mol Sci. 2021 Jun; 22(12): 6468. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235314/

	Solvent	mg/mL	mM
Solubility
	DMSO	15.0	27.75
	DMF	25.0	46.24
	DMF:PBS (pH 7.2) (1:3)	0.3	0.46
	Ethanol	10.0	18.50

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 540.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Li N, Guo XY, Zhou J, Yan XL, Yu FF. Atorvastatin Pretreatment Ameliorates Mesenchymal Stem Cell Migration through miR-146a/CXCR4 Signaling. Tissue Eng Regen Med. 2021 Jul 14. doi: 10.1007/s13770-021-00362-z. Epub ahead of print. PMID: 34260048. 2. Khalighfard S, Khori V, Alizadeh AM, Vahabzadeh G, Tajaldini M, Sedighi S, Nozarian Z, Khodayari H, Khodayari S, Ganji F, Veisi Malekshahi Z, Mirmajidi T. Dual effects of atorvastatin on angiogenesis pathways in the differentiation of mesenchymal stem cells. Eur J Pharmacol. 2021 Jul 1;907:174281. doi: 10.1016/j.ejphar.2021.174281. Epub ahead of print. PMID: 34217710. 3. Zhang XB, Cheng HJ, Yuan YT, Chen Y, Chen YY, Chiu KY, Zeng HQ. Atorvastatin attenuates intermittent hypoxia-induced myocardial oxidative stress in a mouse obstructive sleep apnea model. Aging (Albany NY). 2021 Jul 21;13(undefined). doi: 10.18632/aging.203339. Epub ahead of print. PMID: 34289453. 4. Lastuvkova H, Faradonbeh FA, Schreiberova J, Hroch M, Mokry J, Faistova H, Nova Z, Hyspler R, Igreja Sa IC, Nachtigal P, Stefela A, Pavek P, Micuda S. Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis. Int J Mol Sci. 2021 Jun 16;22(12):6468. doi: 10.3390/ijms22126468. PMID: 34208774; PMCID: PMC8235314.

In vitro protocol:

In vivo protocol:

1. Zhang XB, Cheng HJ, Yuan YT, Chen Y, Chen YY, Chiu KY, Zeng HQ. Atorvastatin attenuates intermittent hypoxia-induced myocardial oxidative stress in a mouse obstructive sleep apnea model. Aging (Albany NY). 2021 Jul 21;13(undefined). doi: 10.18632/aging.203339. Epub ahead of print. PMID: 34289453. 2. Lastuvkova H, Faradonbeh FA, Schreiberova J, Hroch M, Mokry J, Faistova H, Nova Z, Hyspler R, Igreja Sa IC, Nachtigal P, Stefela A, Pavek P, Micuda S. Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis. Int J Mol Sci. 2021 Jun 16;22(12):6468. doi: 10.3390/ijms22126468. PMID: 34208774; PMCID: PMC8235314.

1: Leung YH, Turgeon J, Michaud V. Study of Statin- and Loratadine-Induced Muscle Pain Mechanisms Using Human Skeletal Muscle Cells. Pharmaceutics. 2017 Oct 10;9(4). pii: E42. doi: 10.3390/pharmaceutics9040042. PubMed PMID: 28994701. 2: Menéndez Valladares P, Arrobas Velilla T, Bermúdez de la Vega JA, Romero Pérez MD, Fabiani Romero F, González Rodríguez C. [Increased lipoprotein(a) in a paediatric patient associated with nephrotic syndrome]. Clin Investig Arterioscler. 2016 Sep - Oct;28(5):227-229. doi: 10.1016/j.arteri.2016.06.006. Epub 2016 Sep 9. Spanish. PubMed PMID: 27623226. 3: Ludka FK, Constantino LC, Dal-Cim T, Binder LB, Zomkowski A, Rodrigues AL, Tasca CI. Involvement of PI3K/Akt/GSK-3β and mTOR in the antidepressant-like effect of atorvastatin in mice. J Psychiatr Res. 2016 Nov;82:50-7. doi: 10.1016/j.jpsychires.2016.07.004. Epub 2016 Jul 7. PubMed PMID: 27468164. 4: Niedrig D, Maechler S, Hoppe L, Corti N, Kovari H, Russmann S. Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital: administration of interacting co-medication and QT prolongation. Eur J Clin Pharmacol. 2016 Jul;72(7):859-67. doi: 10.1007/s00228-016-2043-z. Epub 2016 Mar 29. PubMed PMID: 27023463. 5: Mesgarpour B, Gouya G, Herkner H, Reichardt B, Wolzt M. A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death. Lipids Health Dis. 2015 Oct 24;14:131. doi: 10.1186/s12944-015-0134-y. PubMed PMID: 26497728; PubMed Central PMCID: PMC4619489. 6: Schirris TJ, Ritschel T, Bilos A, Smeitink JA, Russel FG. Statin Lactonization by Uridine 5'-Diphospho-glucuronosyltransferases (UGTs). Mol Pharm. 2015 Nov 2;12(11):4048-55. doi: 10.1021/acs.molpharmaceut.5b00474. Epub 2015 Oct 6. PubMed PMID: 26412035. 7: Brilhante RS, Caetano EP, Oliveira JS, Castelo-Branco Dde S, Souza ER, Alencar LP, Cordeiro Rde A, Bandeira Tde J, Sidrim JJ, Rocha MF. Simvastatin inhibits planktonic cells and biofilms of Candida and Cryptococcus species. Braz J Infect Dis. 2015 Sep-Oct;19(5):459-65. doi: 10.1016/j.bjid.2015.06.001. Epub 2015 Jun 26. PubMed PMID: 26119850. 8: Zhang T. Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites. Eur J Pharm Sci. 2015 Sep 18;77:216-29. doi: 10.1016/j.ejps.2015.06.019. Epub 2015 Jun 24. PubMed PMID: 26116278. 9: Hill FJ, McCloskey SJ, Sheerin N. From a fish tank injury to hospital haemodialysis: the serious consequences of drug interactions. BMJ Case Rep. 2015 Jun 23;2015. pii: bcr2015209961. doi: 10.1136/bcr-2015-209961. PubMed PMID: 26106178; PubMed Central PMCID: PMC4480123. 10: Yu Y, Teerenstra S, Neef C, Burger D, Maliepaard M. Investigation into the interchangeability of generic formulations using immunosuppressants and a broad selection of medicines. Eur J Clin Pharmacol. 2015 Aug;71(8):979-90. doi: 10.1007/s00228-015-1878-z. Epub 2015 Jun 12. PubMed PMID: 26062932; PubMed Central PMCID: PMC4500859. 11: Blonk M, van Beek M, Colbers A, Schouwenberg B, Burger D. Pharmacokinetic Drug-Drug Interaction Study Between Raltegravir and Atorvastatin 20 mg in Healthy Volunteers. J Acquir Immune Defic Syndr. 2015 May 1;69(1):44-51. doi: 10.1097/QAI.0000000000000544. PubMed PMID: 25942458. 12: Govindarajan R, Landis M, Hancock B, Gatlin LA, Suryanarayanan R, Shalaev EY. Surface acidity and solid-state compatibility of excipients with an acid-sensitive API: case study of atorvastatin calcium. AAPS PharmSciTech. 2015 Apr;16(2):354-63. doi: 10.1208/s12249-014-0231-7. Epub 2014 Oct 16. PubMed PMID: 25319055; PubMed Central PMCID: PMC4370965. 13: O'Brien E. If I had resistant hypertension. Hypertension. 2014 Nov;64(5):e3-6. doi: 10.1161/HYPERTENSIONAHA.114.04158. Epub 2014 Aug 11. PubMed PMID: 25113965. 14: Higgins JW, Ke AB, Zamek-Gliszczynski MJ. Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1. Drug Metab Dispos. 2014 Nov;42(11):1780-4. doi: 10.1124/dmd.114.058784. Epub 2014 Aug 8. PubMed PMID: 25106415. 15: Vajdič T, Ošlaj M, Kopitar G, Mrak P. Engineered, highly productive biosynthesis of artificial, lactonized statin side-chain building blocks: The hidden potential of Escherichia coli unleashed. Metab Eng. 2014 Jul;24:160-72. doi: 10.1016/j.ymben.2014.05.012. Epub 2014 May 21. PubMed PMID: 24858788. 16: Hamdulay SS, Wang B, Calay D, Kiprianos AP, Cole J, Dumont O, Dryden N, Randi AM, Thornton CC, Al-Rashed F, Hoong C, Shamsi A, Liu Z, Holla VR, Boyle JJ, Haskard DO, Mason JC. Synergistic therapeutic vascular cytoprotection against complement-mediated injury induced via a PKCα-, AMPK-, and CREB-dependent pathway. J Immunol. 2014 May 1;192(9):4316-27. doi: 10.4049/jimmunol.1301702. Epub 2014 Mar 26. PubMed PMID: 24670799. 17: Wanitchanont A, Somparn P, Vadcharavivad S, Chancharoenthana W, Townamchai N, Praditpornsilpa K, Avihingsanon Y. Effects of atorvastatin on the pharmacokinetics of everolimus among kidney transplant recipients. Transplant Proc. 2014;46(2):418-21. doi: 10.1016/j.transproceed.2013.11.121. PubMed PMID: 24655978. 18: Rodrigues LR, de Oliveira DN, Ferreira MS, Catharino RR. In situ assessment of atorvastatin impurity using MALDI mass spectrometry imaging (MALDI-MSI). Anal Chim Acta. 2014 Mar 25;818:32-8. doi: 10.1016/j.aca.2014.01.050. Epub 2014 Feb 4. PubMed PMID: 24626400. 19: Sirén H, Kaijanen L, Kaartinen S, Väre M, Riikonen P, Jernström E. Determination of statins by gas chromatography - EI/MRM - Tandem mass spectrometry: fermentation of pine samples with Pleurotus ostreatus. J Pharm Biomed Anal. 2014 Jun;94:196-202. doi: 10.1016/j.jpba.2014.01.018. Epub 2014 Feb 14. PubMed PMID: 24607418. 20: Robertsen I, Asberg A, Granseth T, Vethe NT, Akhlaghi F, Ghareeb M, Molden E, Reier-Nilsen M, Holdaas H, Midtvedt K. More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. Transplantation. 2014 Jun 27;97(12):1266-71. doi: 10.1097/01.TP.0000443225.66960.7e. PubMed PMID: 24521776; PubMed Central PMCID: PMC4127422.